Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 1/20 | 0.53 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 8/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3488270 | 0.86 | PGR (0.49) | PGRNR3C2ALDH1A1LMNANR1H2 | |
| SCHEMBL3488787 | 0.85 | NR3C2 (0.50) | PGRNR3C2P2RX7NR1H2NR1H3 | |
| SCHEMBL3489982 | 0.84 | SLC2A1 (0.54) | PGRNR3C2NR1H2NR1H3SLC2A1 | |
| SCHEMBL3488088 | 0.81 | SLC2A1 (0.50) | PGRNR3C2ALDH1A1LMNATSHR | |
| SCHEMBL3488481 | 0.79 | PTGS2 (0.43) | PGRNR3C2ALDH1A1 | |
| SCHEMBL3487850 | 0.78 | GRIN1 (0.44) | GRIN2BGRIN1NR1H2NR1H3SLC2A1 | |
| SCHEMBL3488302 | 0.77 | MAPK14 (0.44) | PGRNR3C2GRIN2BGRIN1ALDH1A1 | |
| SCHEMBL3488053 | 0.77 | NR3C2 (0.52) | NR3C2GRIN2BGRIN1P2RX7ALDH1A1 | |
| SCHEMBL3489605 | 0.77 | SLC2A1 (0.40) | PGRNR3C2ALDH1A1NR1H2NR1H3 | |
| SCHEMBL3488094 | 0.77 | SLC2A1 (0.40) | PGRNR3C2ALDH1A1LMNANR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100094000-A1 | PYRAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20100094000-A1 | PYRAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20100094000-A1 | PYRAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100094000-A1 | PYRAZOLE COMPOUNDS | NR3C2, MC2R, NR3C1 | PGR 107/4885NR3C2 1/4885GRIN2B 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.